Valaciclovir
- Generic Name
- Valaciclovir
- Brand Names
- Valtrex
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N6O4
- CAS Number
- 124832-26-4
- Unique Ingredient Identifier
- MZ1IW7Q79D
- Background
Valaciclovir (valacyclovir), also known as Valtrex, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 and marketed by GlaxoSmithKline . Valacyclovir is the L-valine ester of aciclovir. It is a member of the purine (guanine) nucleoside analog drug class . This class of drugs forms an important part of hepatitis, HIV, and cytomegalovirus drug regimens .
One major use of valacyclovir is the treatment of genital herpes episodes or outbreaks. Genital herpes is a frequently diagnosed sexually transmitted disease which currently affects more than 400 million individuals worldwide. It is caused by infection with the herpes simplex virus (HSV). Infection with this virus is lifelong with periodic episodes of reactivation .
- Indication
Valacyclovir is a nucleoside analog DNA polymerase inhibitor indicated for :
Adults
• Cold Sores (Herpes Labialis)
• Genital Herpes
• Treatment of genital herpes lesions in immunocompetent patients (initial or recurrent episode)
• Suppression of genital herpes lesions in immunocompetent or HIV-infected patients
• Reduction of viral transmission
• Herpes Zoster
Pediatric Patients
• Cold Sores (Herpes Labialis)
• Chickenpox
Limitations of use
The efficacy and safety of valacyclovir have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.
- Associated Conditions
- Chickenpox, Genital Herpes, Genital herpes, initial episode, Herpes Labialis, Herpes Zoster, Recurrent Genital Herpes (RGH)
- Associated Therapies
- Suppression of Recurrent Genital Herpes (RGH)
Cancer Vaccines Emerge as Promising Frontier in Oncology with Multiple Approaches Showing Clinical Success
• Cancer vaccines are gaining momentum across multiple tumor types, with FDA-approved options like BCG, sipuleucel-T, and talimogene laherparepvec demonstrating clinical utility in bladder cancer, prostate cancer, and melanoma respectively.
• Novel vaccine approaches including mRNA-based mRNA-4157, KRAS-targeted ELI-002, and viral vector-based aglatimagene besadenovec are showing promising results in clinical trials, with significant improvements in survival outcomes across various cancers.
• Experts believe cancer vaccines hold particular promise in early-stage and high-risk disease settings by targeting micrometastatic disease, potentially increasing cure rates and transforming treatment paradigms when combined with existing immunotherapies.
Dogwood Therapeutics Converts $19.5M Debt to Equity, Advances Phase 2b Trial of Non-Opioid Pain Treatment
• Dogwood Therapeutics has strengthened its financial position by converting $19.5 million in debt to equity, removing all existing debt from its balance sheet and improving its investment profile.
• The company has commenced dosing in its Phase 2b trial of Halneuron®, a first-in-class NaV 1.7 sodium channel inhibitor being developed as a non-opioid treatment for chemotherapy-induced neuropathic pain (CINP).
• With a recent $4.8 million capital raise and the debt conversion, Dogwood now has sufficient operational runway through Q1 2026, with interim data from the CINP trial expected in Q4 2025.
Herpes Zoster Vaccine Shows Strong Protection for Stem Cell Transplant Recipients, Meta-Analysis Reveals
• A comprehensive meta-analysis of 3,048 hematopoietic stem cell transplant recipients demonstrates that herpes zoster vaccine reduces infection risk by 64%, with infection rates dropping from 18.3% to 6.4%.
• The vaccine showed promising results in reducing post-herpetic neuralgia and other complications, while maintaining a favorable safety profile with no significant increase in adverse events.
• Research primarily focused on autologous transplant recipients, highlighting the need for additional studies in allogeneic transplant populations to confirm vaccine efficacy and safety.
Theralase's Ruvidar® Shows Complete Healing of HSV-1 Lesions in Preclinical Study
• Theralase's topical Ruvidar® treatment demonstrated complete healing of HSV-1 cutaneous lesions in mice after four days of application, marking a significant breakthrough in herpes treatment.
• The non-light activated therapy showed promising safety and efficacy in animal models, potentially offering new hope for billions affected by HSV infections worldwide.
• Researchers plan to advance the development of both a therapeutic treatment and preventive vaccine for HSV, with clinical trials to follow these successful preclinical results.
Faricimab Rechallenge Linked to Severe Vision Loss in Patients with Prior Inflammation
A new case series reports three patients who developed severe occlusive retinal vasculitis following rechallenge with faricimab after initial mild inflammation. The study from the University of Nebraska Medical Center suggests avoiding drug rechallenge in patients who experience inflammatory reactions to anti-VEGF medications, as it may lead to irreversible vision loss.
Dogwood Therapeutics Initiates Phase 2b Trial of Halneuron® for Chemotherapy-Induced Neuropathic Pain
• Dogwood Therapeutics has commenced patient dosing in a Phase 2b trial (HALT-CINP) to evaluate Halneuron® for chemotherapy-induced neuropathic pain (CINP).
• Halneuron®, a first-in-class Nav 1.7 inhibitor, offers a non-opioid alternative for managing chronic pain associated with chemotherapy.
• The trial targets a significant unmet medical need, with the CINP market estimated at $1.5 billion, addressing the ineffectiveness of current treatments.
• Interim data from the Phase 2 CINP study are anticipated in the second half of 2025, marking a key milestone for the drug's development.
Candel Therapeutics Highlights Pipeline Momentum with CAN-2409 and CAN-3110
• Candel Therapeutics is set to report updated overall survival data for CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer in Q1 2025.
• The company is preparing for a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer, expected in Q4 2026.
• Phase 3 clinical trial data for CAN-2409 in prostate cancer will be presented at upcoming scientific conferences, marking a key milestone.
• Overall survival data from the Phase 1b trial of CAN-3110 in recurrent high-grade glioma is anticipated in Q4 2025.
Pancreatic Cancer: Advances in Treatment and Research Bring Hope in 2024
• The five-year relative survival rate for pancreatic cancer has risen to 13%, marking the third consecutive year of improvement, yet it remains the lowest among major solid tumors.
• Four new drug approvals for pancreatic cancer occurred in 2024, including one first-line treatment and three targeted agents for previously treated advanced disease.
• A Phase 3 clinical trial demonstrated an overall survival benefit using Tumor Treating Fields (TTFields) in combination with chemotherapy for unresectable, locally advanced pancreatic cancer.
• Precision medicine is advancing with the FDA approval of Bizengri for NRG1 fusion-positive pancreatic cancer and the ongoing RASolute 302 trial evaluating RMC-6236, a RAS inhibitor.
CAN-2409 Viral Immunotherapy Shows Promise in Localized Prostate Cancer
• CAN-2409, combined with valacyclovir and radiation, significantly improved disease-free survival (DFS) in intermediate- to high-risk localized prostate cancer patients.
• The Phase 3 PrTK03 trial demonstrated a 30% reduction in disease recurrence or death with CAN-2409 compared to standard of care radiation therapy alone.
• Patients treated with CAN-2409 exhibited an 80.4% pathological complete response rate at two years, versus 63.6% in the control group.
• Candel Therapeutics plans to engage with the FDA to explore regulatory approval pathways for CAN-2409 in this indication.
Candel Therapeutics' CAN-2409 Achieves Primary Endpoint in Phase III Prostate Cancer Trial
• Candel Therapeutics' CAN-2409, combined with radiation therapy, significantly improved disease-free survival in localized prostate cancer patients in a Phase III trial.
• The study demonstrated a 14.5% relative improvement in disease-free survival at 54 months compared to the placebo arm.
• CAN-2409 showed a statistically significant effect on prostate cancer-free survival and increased the proportion of patients achieving a prostate-specific antigen nadir.
• Candel plans to discuss the regulatory pathway for CAN-2409 with the FDA, potentially offering a new treatment option for localized prostate cancer.
Cell and Gene Therapies Show Promise in Lung Cancer Treatment
• Kiromic BioPharma's Deltacel T-cell therapy demonstrates disease stabilization in NSCLC patients, showing potential in advanced solid tumor treatment.
• Achilles Therapeutics advances neoantigen reactive T-cell therapy trials for NSCLC and melanoma, observing improved T-cell persistence with enhanced conditioning.
• Genprex reports positive results in two lung cancer trials for Reqorsa gene therapy, while discontinuing another, focusing on optimal patient cohorts.
• Viral immunotherapy combo CAN-2409 improves survival in NSCLC patients unresponsive to anti-PD-L1 therapy, reactivating exhausted immune systems.
AAO 2024: 3D-Printed Glasses, ANX007 for Geographic Atrophy, and Cataract Surgery Risks Highlighted
• Customizable 3D-printed glasses offer a cost-effective solution for pediatric patients with complex eye conditions like amblyopia and strabismus, improving access to specialized eyewear.
• ANX007, a C1q inhibitor, demonstrates dose- and time-dependent protection against vision loss in patients with geographic atrophy, preserving retinal anatomy in a Phase 2 trial.
• Prior intravitreal injections (IVIs) increase the risk of complications following cataract surgery, including vitreous hemorrhage and retinal detachment, necessitating careful surgical planning.
Low-Dose Antiviral Therapy Reduces Risk of Eye Disease from Shingles
• Long-term, low-dose valacyclovir reduces the risk of new or worsening eye disease by 26% in patients with herpes zoster ophthalmicus (HZO).
• The Zoster Eye Disease Study (ZEDS) found a 30% reduction in flare-ups at 12 months and 28% at 18 months with antiviral therapy.
• The treatment also shortened pain duration and decreased the need for medications like pregabalin and gabapentin.
• Experts emphasize shingles vaccination with Shingrix for adults 50 and older, and immunocompromised adults 19 and older.
Virios Therapeutics and Wex Pharmaceuticals Merge to Form Dogwood Therapeutics, Advancing Novel Pain and Viral Therapies
• Virios Therapeutics and Wex Pharmaceuticals have merged in an all-stock transaction, creating Dogwood Therapeutics (NASDAQ: DWTX), focused on clinical development of Halneuron®, IMC-1, and IMC-2.
• The merger includes a $19.5 million financing to advance Halneuron®, a non-opioid NaV1.7 inhibitor for chemotherapy-induced neuropathic pain, with Phase 2b interim results expected in 2H25.
• Dogwood Therapeutics will grant existing VIRI stockholders a contingent value right (CVR) tied to potential milestone payments from partnering transactions for IMC-1 (fibromyalgia) and IMC-2 (Long-COVID).
• A 25-for-1 reverse stock split was executed to enable the business combination and Nasdaq listing compliance, with Dogwood Therapeutics trading under the ticker symbol "DWTX" starting October 9, 2024.
Phase 3 Trials Target Advanced Prostate Cancer with Novel Therapies
• A Phase 3 trial is underway to assess CAN-2409 immunotherapy combined with radiation for localized prostate cancer, aiming to improve disease-free survival.
• Johnson & Johnson's Akeega, combining niraparib and abiraterone, is being evaluated in the AMPLITUDE study for metastatic castration-sensitive prostate cancer with HRR mutations.
• Pfizer's mevrometostat, an EZH2 inhibitor, is under investigation in the MEVPRO-1 trial for metastatic castration-resistant prostate cancer after abiraterone treatment.
Rare Shingles Reactivation Reported Post-Shingrix Vaccination
• A recent study highlights a rare case of herpes zoster ophthalmicus (HZO) reactivation following recombinant zoster vaccine (RZV) administration in a 59-year-old male.
• The patient developed a rash and paresthesia nine days post-vaccination, requiring hospitalization and treatment with valacyclovir and mupirocin.
• While RZV (Shingrix) is generally safe and effective, this case underscores the need for ongoing monitoring for potential adverse events and rare reactivation.
• Further research is necessary to understand how RZV's immunomodulatory effects may, in rare instances, provoke herpes zoster reactivation.
Extended-Course Nirmatrelvir/Ritonavir Shows Promise in Treating Long COVID Symptoms
A series of case studies highlights the potential benefits of extended-course nirmatrelvir/ritonavir treatment for individuals suffering from Long COVID, with some patients reporting significant improvements in symptoms. The treatment, typically used for acute COVID-19 infections, was administered outside of the acute phase, offering new insights into managing Long COVID.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath